[go: up one dir, main page]

NI201000203A - DERIVADOS DE UREA MACROCÍCLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa. - Google Patents

DERIVADOS DE UREA MACROCÍCLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa.

Info

Publication number
NI201000203A
NI201000203A NI201000203A NI201000203A NI201000203A NI 201000203 A NI201000203 A NI 201000203A NI 201000203 A NI201000203 A NI 201000203A NI 201000203 A NI201000203 A NI 201000203A NI 201000203 A NI201000203 A NI 201000203A
Authority
NI
Nicaragua
Prior art keywords
inhibitors
tafia
sulfamide
derivatives
macrocyclic urea
Prior art date
Application number
NI201000203A
Other languages
English (en)
Inventor
Kallus Christopher
Wagner Michael
Broenstrup Mark
Evers Andreas
Globisch Anja
Schreuder Herman
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of NI201000203A publication Critical patent/NI201000203A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a compuestos de fórmula (I) que son inhibidores de la fibrinolisis activable por trombina activada. Los compuestos de la fórmula I son adecuados para la fabricación de medicamentos para la profilaxis, prevención secundaria y terapia de uno o más trastornos asociados con trombosis, embolias, hipercoagulabilidad o cambios fibróticos.
NI201000203A 2008-06-06 2010-11-22 DERIVADOS DE UREA MACROCÍCLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa. NI201000203A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06

Publications (1)

Publication Number Publication Date
NI201000203A true NI201000203A (es) 2011-09-29

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000203A NI201000203A (es) 2008-06-06 2010-11-22 DERIVADOS DE UREA MACROCÍCLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa.

Country Status (34)

Country Link
US (5) US8580777B2 (es)
EP (1) EP2300462B1 (es)
JP (1) JP5531011B2 (es)
KR (1) KR101673886B1 (es)
CN (1) CN102056922B (es)
AR (1) AR072007A1 (es)
AU (1) AU2009254257B2 (es)
BR (1) BRPI0913349A2 (es)
CA (1) CA2726554C (es)
CL (1) CL2009001358A1 (es)
CO (1) CO6321271A2 (es)
CR (1) CR11807A (es)
CY (1) CY1115604T1 (es)
DK (1) DK2300462T3 (es)
DO (1) DOP2010000363A (es)
EC (1) ECSP10010655A (es)
ES (1) ES2494390T3 (es)
HN (1) HN2010002558A (es)
HR (1) HRP20140787T1 (es)
IL (1) IL209772A (es)
MA (1) MA32322B1 (es)
MX (1) MX2010012793A (es)
NI (1) NI201000203A (es)
NZ (1) NZ589671A (es)
PL (1) PL2300462T3 (es)
PT (1) PT2300462E (es)
RU (1) RU2502736C2 (es)
SI (1) SI2300462T1 (es)
SV (1) SV2010003747A (es)
TW (1) TWI455928B (es)
UA (1) UA104002C2 (es)
UY (1) UY31868A (es)
WO (1) WO2009146802A1 (es)
ZA (1) ZA201007719B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2300462B1 (de) 2008-06-06 2014-05-21 Sanofi Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia
AR072278A1 (es) 2008-06-23 2010-08-18 Astrazeneca Ab Compuestos inhibidores de trombina
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
BR112014022106B1 (pt) * 2012-03-06 2022-08-02 Pfizer Inc Derivados macrocíclicos, combinação, composição e usos na fabricação de um medicamento para o tratamento de doenças
JP6461113B2 (ja) * 2013-06-10 2019-01-30 サノフイＳａｎｏｆｉ ＴＡＦＩａの阻害剤としての大環状尿素誘導体、それらの製造および医薬としての使用
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
DE69824433D1 (en) 1997-08-28 2004-07-15 Biovitrum Ab Proteintyrosinphosphatase inhibitoren
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
DE60042585D1 (de) * 2000-02-29 2009-09-03 Univ Firenze 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
PL2104497T3 (pl) 2006-12-06 2015-07-31 Sanofi Sa Pochodne sulfamidu jako inhibitory TAFIa
EP2300462B1 (de) 2008-06-06 2014-05-21 Sanofi Makrocyclische harnstoff- und sulfamidderivate als inhibitoren von tafia

Also Published As

Publication number Publication date
MA32322B1 (fr) 2011-05-02
AU2009254257B2 (en) 2013-11-21
ECSP10010655A (es) 2011-01-31
IL209772A (en) 2016-04-21
IL209772A0 (en) 2011-02-28
ES2494390T3 (es) 2014-09-15
CN102056922A (zh) 2011-05-11
TW201008917A (en) 2010-03-01
EP2300462A1 (de) 2011-03-30
US20160024033A1 (en) 2016-01-28
WO2009146802A1 (de) 2009-12-10
HK1152936A1 (en) 2012-03-16
UA104002C2 (ru) 2013-12-25
CA2726554A1 (en) 2009-12-10
US9126955B2 (en) 2015-09-08
CR11807A (es) 2011-02-16
TWI455928B (zh) 2014-10-11
BRPI0913349A2 (pt) 2015-11-24
US8722655B2 (en) 2014-05-13
PT2300462E (pt) 2014-08-05
CA2726554C (en) 2015-02-24
CY1115604T1 (el) 2017-01-04
AU2009254257A1 (en) 2009-12-10
SI2300462T1 (sl) 2014-09-30
US9309207B2 (en) 2016-04-12
AR072007A1 (es) 2010-07-28
DK2300462T3 (da) 2014-08-18
RU2010154089A (ru) 2012-07-20
CO6321271A2 (es) 2011-09-20
CL2009001358A1 (es) 2009-11-27
EP2300462B1 (de) 2014-05-21
KR20110020795A (ko) 2011-03-03
HN2010002558A (es) 2012-08-28
PL2300462T3 (pl) 2014-10-31
KR101673886B1 (ko) 2016-11-08
JP2011521981A (ja) 2011-07-28
HRP20140787T1 (hr) 2014-11-21
JP5531011B2 (ja) 2014-06-25
NZ589671A (en) 2012-03-30
DOP2010000363A (es) 2010-12-15
US20140039011A1 (en) 2014-02-06
US20160251324A1 (en) 2016-09-01
US8580777B2 (en) 2013-11-12
RU2502736C2 (ru) 2013-12-27
ZA201007719B (en) 2011-07-27
US9688645B2 (en) 2017-06-27
CN102056922B (zh) 2013-11-20
US20140206760A1 (en) 2014-07-24
SV2010003747A (es) 2011-03-15
MX2010012793A (es) 2010-12-14
US20110178130A1 (en) 2011-07-21
UY31868A (es) 2010-01-05

Similar Documents

Publication Publication Date Title
NI201000203A (es) DERIVADOS DE UREA MACROCÍCLICOS Y DE SULFAMIDA COMO INHIBIDORES DE TAFIa.
MX2018006148A (es) Inhibidores de cxcr2.
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
PH12016500072A1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
MX374439B (es) Compuesto de piridona como inhibidor de c-met
CR20110440A (es) Compuestos de piridazinona
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
CO6511220A2 (es) Quinazolinas como inhibidores de los canales iónicos de potasio
EA201200917A1 (ru) Пролекарства ингибиторов плазменного калликреина
BR112016014412A2 (pt) Compostos de diaminopirimidil substituído, composições do mesmo, e métodos de tratamento com o mesmo
CR20130024A (es) Compuestos heterocíclicos fusionados
DOP2014000033A (es) Aminoquinazolinas como inhibidores de quinasa
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
MX2017008048A (es) Derivados de 5-[(piperazin-1-il)-3-oxopropil]-imidazolidin-2,4-dio na como inhibidores de desintegrina y metaloproteinasa con motivos de trombospondina (adamts) para el tratamiento de osteoartritis.
PH12015502611A1 (en) Heterocyclic compounds as hedgehog signaling pathway inhibitors
NI200600217A (es) Derivados de imidazol utilizados como inhibidores de tafia
UY33701A (es) Derivados arilo y heteroarilcarbonilo de hexahidroindenopiridina y octahidrobenzoquinolina
NO20092246L (no) Urea og sulfamidderivater som tafiainhibitorer
CR20140564A (es) Derivados de pirimidinona como agentes antimaláricos
MX373646B (es) Halogeno-pirazoles como inhibidores de trombina.
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
BR112017022032A2 (pt) métodos para tratamento de transtornos de armazenamento lisossômico
CL2012001606A1 (es) Compuestos derivados de tiazoles bicíclicos como moduladores alostéricos de receptores mglur5; composición farmacéutica que los comprende; procedimiento de preparación de la composición farmacéutica; combinación farmacéutica; y uso del compuesto en la prevención, tratamiento o profilaxis de trastornos neurológicos o psiquiátricos.
ECSP11011150A (es) Derivados de arilciclopropilacetamida útiles como activadores de glucoquinasa